A nomogram for predicting low-volume/low-grade prostate cancer - A tool in selecting patients for active surveillance

被引:60
|
作者
Nakanishi, Hiroyuki
Wang, Xuemei
Ochiai, Atsushi
Trpkov, Kiril
Yilmaz, Asli
Donnelly, J. Bryan
Davis, John W.
Troncoso, Patricia
Babaian, R. Joseph
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA
[3] Univ Calgary, Dept Pathol & Lab Med, Calgary Lab Sci, Calgary, AB T2N 1N4, Canada
[4] Univ Calgary, Dept Urol, Calgary, AB T2N 1N4, Canada
[5] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
关键词
nomogram; extended biopsy; low-volume/low-grade prostate cancer; tumor volume; significant cancer; prostatectomy; prediction model; active surveillance;
D O I
10.1002/cncr.23055
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. The authors reported previously that assessment of the number of positive biopsy cores, maximum tumor length in a core, Gleason score, and prostate volume in an extended biopsy enhanced the accuracy of predicting low-volume/low-grade prostate cancer. On the basis of those findings, they developed a nomogram to predict the probability of low-volume/low-grade prostate cancer specifically for men with a single positive biopsy core. METHODS. The study cohort comprised 258 men who underwent radical prostatectomy without neoadjuvant therapy. Prostate cancer was diagnosed in only 1 core of an extended biopsy scheme. Low-volume/low-grade cancer was defined as pathologic organ-confined disease and a tumor volume < 0.5 cc with no Gleason grade 4 or 5 cancer. Patient age, prostate-specific antigen (PSA) level, prostate volume, PSA density (PSAD), and turner length in a biopsy core were examined as variables. A fitted multiple logistic regression model was used to establish the nomogram. RESULTS. One hundred thirty-three patients (51.6%) had low-volume/low-grade cancer. To establish the nomogram, age, PSAD, and tumor length were adopted as variables. The fitted model suggested that older age, higher PSAD values, and greater tumor length would reduce the probability of low-volume/low-grade cancer. The nomogram predicted low-volume/low-grade cancer with good discrimination (an area under the receiver operating characteristic Curve of 0.727). Calibration of this nomogram showed good predicted probability. CONCLUSIONS. The authors established a nomogram with which to predict low-volume/low-grade cancer in men with 1 positive biopsy core in an extended biopsy scheme, and they recommend this nomogram for use in selecting men for active surveillance.
引用
收藏
页码:2441 / 2447
页数:7
相关论文
共 50 条
  • [21] Active Surveillance for Low-Risk Prostate Cancer
    Laurence Klotz
    Current Urology Reports, 2015, 16
  • [22] Active Surveillance for Low-risk Prostate Cancer
    Mazzucchelli, Roberta
    Nesseris, Ioannis
    Cheng, Liang
    Lopez-Beltran, Antonio
    Montironi, Rodolfo
    Scarpelli, Marina
    ANTICANCER RESEARCH, 2010, 30 (09) : 3683 - 3692
  • [23] Active surveillance for low-risk prostate cancer
    Hadjipavlou, Marios
    Promponas, John
    Madaan, Sanjeev
    JOURNAL OF CLINICAL UROLOGY, 2015, 8 (06) : 420 - 428
  • [24] Cancer Detection Rate and Abnormal Interpretation Rate of Prostate MRI in Patients With Low-Grade Cancer
    Nakai, Hirotsugu
    Nagayama, Hiroki
    Takahashi, Hiroaki
    Froemming, Adam T.
    Kawashima, Akira
    Bolan, Candice W.
    Adamo, Daniel A.
    Carter, Rickey E.
    Fazzio, Robert T.
    Tsuji, Shintaro
    Lomas, Derek J.
    Mynderse, Lance A.
    Humphreys, Mitchell R.
    Dora, Chandler
    Takahashi, Naoki
    JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY, 2024, 21 (03) : 387 - 397
  • [25] Pharmacokinetic MRI of the Prostate: Parameters for Differentiating Low-Grade and High-Grade Prostate Cancer
    Franiel, T.
    Luedemann, L.
    Taupitz, M.
    Rost, J.
    Asbach, P.
    Beyersdorff, D.
    ROFO-FORTSCHRITTE AUF DEM GEBIET DER RONTGENSTRAHLEN UND DER BILDGEBENDEN VERFAHREN, 2009, 181 (06): : 536 - 542
  • [26] Active Surveillance for Low-Risk Prostate Cancer
    Klotz, Laurence
    CURRENT UROLOGY REPORTS, 2015, 16 (04) : 1 - 10
  • [27] Selecting Active Surveillance: Decision-Making Factors for Men with a Low-Risk Prostate Cancer
    Hoffman, Richard M.
    Lobo, Tania
    Van Den Eeden, Stephen K.
    Davis, Kimberly M.
    Luta, George
    Leimpeter, Amethyst D.
    Aaronson, David
    Penson, David F.
    Taylor, Kathryn
    MEDICAL DECISION MAKING, 2019, 39 (08) : 962 - 974
  • [28] Prostate Cancer Antigen 3 Score Accurately Predicts Tumour Volume and Might Help in Selecting Prostate Cancer Patients for Active Surveillance
    Ploussard, Guillaume
    Durand, Xavier
    Xylinas, Evanguelos
    Moutereau, Stephane
    Radulescu, Camelia
    Forgue, Aurelien
    Nicolaiew, Nathalie
    Terry, Stephane
    Allory, Yves
    Loric, Sylvain
    Salomon, Laurent
    Vacherot, Francis
    de la Taille, Alexandre
    EUROPEAN UROLOGY, 2011, 59 (03) : 422 - 429
  • [29] Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer
    Rounbehler, Robert J.
    Berglund, Anders E.
    Gerke, Travis
    Takhar, Mandeep M.
    Awasthi, Shivanshu
    Li, Weimin
    Davicioni, Elai
    Erho, Nicholas G.
    Ross, Ashley E.
    Schaeffer, Edward M.
    Klein, Eric A.
    Karnes, R. Jeffrey
    Jenkins, Robert B.
    Cleveland, John L.
    Park, Jong Y.
    Yamoah, Kosj
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2018, 27 (11) : 1376 - 1383
  • [30] A proposal of a new nomogram for predicting upstaging in contemporary D'Amico low-risk prostate cancer patients
    Leyh-Bannurah, Sami-Ramzi
    Dell'Oglio, Paolo
    Tian, Zhe
    Schiffmann, Jonas
    Shariat, Shahrokh F.
    Suardi, Nazareno
    Francesco, Montorsi
    Alberto, Briganti
    Heinzer, Hans
    Huland, Hartwig
    Graefen, Markus
    Budaeus, Lars
    Karakiewicz, Pierre I.
    WORLD JOURNAL OF UROLOGY, 2017, 35 (02) : 189 - 197